Phase 1 Ovarian Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You must be at least 18 years old when you sign the consent form to participate.
- You must be willing and able to sign a written consent form agreeing to take part.
- You must have an advanced or spreading solid tumor cancer that has gotten worse after standard treatments, or where no standard treatment exists.
- Your tumor must have a specific genetic change called "TP53 R175H mutation," confirmed by an approved laboratory test.
- You must have a specific immune system marker called "HLA-A*02:01," confirmed by a central test.
- You must be generally well enough to carry out daily activities with little or no limitation (a standard health scale called ECOG must score you at 0 or 1).
- Your blood, kidney, and liver function must be at an acceptable level.
- You must be willing and able to attend all required study visits and follow the study rules, in your doctor's judgment.
Who may not be able to join:
- You cannot join if you have an inherited condition called Li-Fraumeni syndrome, or any other inherited form of the TP53 R175H genetic change.
- You cannot join if you have previously received a treatment specifically targeting the TP53 R175H mutation.
- You cannot join if you are still experiencing significant side effects from a previous cancer treatment.
- You cannot join if you currently have an active infection that requires antibiotic or antifungal medication taken throughout the body.
- You cannot join if you have had another separate cancer in the past 2 years, with some exceptions such as certain skin cancers, early-stage cancers that haven't spread, or prostate cancer that is in remission (confirm with trial site).
- You cannot join if you have active cancer that has spread to the brain or the lining around the brain and spinal cord.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: +1-617-812-1431
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Part A: Determine the maximum tolerated dose (MTD) and/or the recommended dose(s) for expansion (RDE[s]); Part B: Evaluate the Objective response rate (ORR) of CLSP-1025 as a monotherapy in HLA-selected patients with advanced solid tumors that express the p53 R175H mutation
Can't join this trial?
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.